Whilst COVID-19 continues to be rather all-consuming, we’ve been extremely fortunate signing all relevant contracts at the start of the pandemic enabling us to keep the momentum of ChariotMS. Recruitment was meant to start this month, however COVID-19 threw us a final dummy, and we are now on course to enrol the first participant in Jan 2021.
I can hardly describe how excited I am this trial is finally getting underway in earnest. What started as a chat between MouseDoctor and myself almost exactly eight years ago will finally see the light of day. Over those years, and through the ups and downs of several rejections, we built an ever stronger network of supporters. Neurologists, scientists, trial managers, pwMS, and many more joined in developing the program, making the case to convince the NIHR-EME, MS Societies in the UK and US, Barts Charity and Merck KGaA. Thanks to them, standing on the shoulders of early seed-corn supporters, such as the Morris-Saady Charitable Trust, Lipomed, the North Thames Clinical Trials Network and others, ChariotMS will happen, and hopefully underpin that targeted immunotherapy is beneficial at any stage of MS.
As we’re getting ready, I will over the next few weeks introduce you in more detail to ChariotMS, key people involved, and what further we have up our sleeves. The slides above and below are from our presentation at MSVirtual. I will put the full deck on Twitter (@KlausSchmierer) once the meeting has kicked off Friday afternoon. You can find the abstract here (P0196).